Jefferies analyst Cui Cui maintained a Buy rating on Wuxi Biologics (Cayman) (WXIBF – Research Report) today and set a price target of ...
We forecast WuXi's revenue growth to be slower than that of other well-established peers. The risk is high that the US Biosecure Act will become law, and we expect global pharmaceutical or ...
Vietnam Investment Review on MSN6d
WuXi Biologics Posts Strong 2024 Results Forecasts Rapid Growth in 2025Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...
WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...
Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...
WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...
Vietnam Investment Review on MSN11d
WuXi Biologics Named to CDP Water Security A List for Second Consecutive YearLaunching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6) Contributing to the 2025 World Water Day campaign to ensure the availability of water and ...
Der Deutsche Bundeswehrverband fordert mehr Anstrengungen zur Personalgewinnung bei der Bundeswehr. „Jetzt muss ein Ruck durch Deutschland gehen, was die Verteidigungsfähigkeit anbelangt ...
Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...
Ranking in top 1% of S&P Global CSA Score Inclusion in Global Yearbook for third consecutive year Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback